Refractory immune thrombocytopenia (ITP): the marrow before the pill
A man has carried a diagnosis of immune thrombocytopenia for twenty years. Steroids, immunoglobulin, rituximab, splenectomy. Platelets sit under 30 (thousands) and he has never bled. A thrombopoietin agonist is prescribed. Then a flow cytometry report mentions monocytosis and eosinophilia.
Concepts first
Why the marrow comes first
TPO thrombopoietin, the hormone that drives platelet production · megakaryocyte the marrow cell that sheds platelets · flow cytometry counts and types blood cells by surface markers; it flagged the monocytes here
The drug is safe for the marrow. The problem is reading the marrow after it.The marrow is not routine in immune thrombocytopenia: with a typical presentation it is not needed at any age (Neunert 2011). Do it for an abnormality in another lineage or on the smear (monocytosis and eosinophilia count), for no response to first-line therapy, for relapse after remission, or before splenectomy (Provan 2019). This man ticks two.
Decide in clinic
Weekly blood counts in a patient who is not bleeding and not on a new drug tell you nothing you will act on. Count him when the plan changes.
Sources
Retrieved from PubMed, read on Oct 22, 2026.
- Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009. doi:10.1182/blood-2008-07-162503
- Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011. doi:10.1182/blood-2010-08-302984
- Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 2019. doi:10.1182/bloodadvances.2019000966
- Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 2019. doi:10.1182/bloodadvances.2019000812
- Kuter DJ, Mufti GJ, Bain BJ, et al. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood 2009. doi:10.1182/blood-2009-05-224766
- Brynes RK, Orazi A, Theodore D, et al. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: data from the EXTEND study. Am J Hematol 2015. doi:10.1002/ajh.24011
- Miltiadous O, Hou M, Bussel JB. Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. Blood 2020. doi:10.1182/blood.2019003599
- Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia 2022. doi:10.1038/s41375-022-01613-1
Squamous cell carcinoma of the scalp, found late
A man kept a sore on his scalp under a cap for years. It was noticed during an admission for something else, called "infected", and treated with amoxicillin. Months later he arrives with a fungating tumor eroding the skull, a second ulcer behind it, and a firm nodule in front of the ear.
Concepts first
Where a scalp cancer goes, and where the scan must look
PET positron emission tomography with a glucose tracer; shows metabolically active tumor · vertex the top of the skull · PD-1 a brake on T cells; blocking it lets them attack the tumor · PD-L1 the tumor-side partner of PD-1
A nodule in front of the ear on a patient with a scalp cancer is a parotid node until the PET says otherwise.The parotid and upper neck nodes are where skin squamous cancer of the anterior scalp, temple and ear spreads first (Veness 2007); in Australian series metastatic skin cancer is the commonest parotid malignancy (O'Brien 2002). A parotid node moves the patient from locally advanced to regional disease, and it is the reason the systemic drug is not optional.
What the immunotherapy trials showed
Tell the patient "about half" for cemiplimab and mean it. Pembrolizumab in recurrent or metastatic disease was closer to a third.Responses are durable: in the metastatic cohort, 82% of responders were still responding at data cutoff (Migden 2018), and that 82% is the number most often misremembered as the response rate. Median response duration was not reached in either pembrolizumab cohort (Hughes 2021).
Decide in clinic
A draining, foul tumor is not an infection. If the discharge summary says amoxicillin, the diagnosis has not been made yet.
Sources
Retrieved from PubMed, read on Oct 22, 2026.
- Lydiatt WM, Patel SG, O'Sullivan B, et al. Head and neck cancers: major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017. doi:10.3322/caac.21389
- Brantsch KD, Meisner C, Schönfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 2008. doi:10.1016/S1470-2045(08)70178-5
- Veness MJ, Porceddu S, Palme CE, Morgan GJ. Cutaneous head and neck squamous cell carcinoma metastatic to parotid and cervical lymph nodes. Head Neck 2007. doi:10.1002/hed.20576
- O'Brien CJ, McNeil EB, McMahon JD, et al. Significance of clinical stage, extent of surgery, and pathologic findings in metastatic cutaneous squamous carcinoma of the parotid gland. Head Neck 2002. doi:10.1002/hed.10063
- Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 2018. doi:10.1056/NEJMoa1805131
- Migden MR, Khushalani NI, Chang ALS, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol 2020. doi:10.1016/S1470-2045(19)30728-4
- Grob JJ, Gonzalez R, Basset-Seguin N, et al. Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629). J Clin Oncol 2020. doi:10.1200/JCO.19.03054
- Hughes BGM, Munoz-Couselo E, Mortier L, et al. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Ann Oncol 2021. doi:10.1016/j.annonc.2021.07.008
- Gross ND, Miller DM, Khushalani NI, et al. Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med 2022. doi:10.1056/NEJMoa2209813
Small mediastinal nodes in a young adult with a cough
A woman in her twenties has had a dry cough for four months, with chills and fatigue in flares, and aching hips and hands. Chest CT: several small mediastinal nodes, normal hila, nothing in the lung. Blood counts and chemistry are normal. A close relative has sarcoidosis, found only after months of empirical tuberculosis treatment. She travels to histoplasma country: Mexico, Central America.
Concepts first
Getting the tissue
PET positron emission tomography, a glucose-tracer scan that lights up active tissue · EBUS endobronchial ultrasound, a bronchoscope with an ultrasound tip that guides a needle into nodes through the airway · LDH lactate dehydrogenase, a blood enzyme that rises with cell turnover and bulky lymphoma · stage I and II chest nodes alone, or nodes plus lung shadows
The angiotensin-converting enzyme does not make or break the diagnosis.The American Thoracic Society panel made one strong recommendation, baseline serum calcium in every diagnosed patient, and 13 conditional ones; none concerns the enzyme, which appears only as a "probable" supporting feature (Crouser 2020). A normal enzyme excludes nothing, and a high one proves nothing.
Decide in clinic
The relative treated for tuberculosis for months had the biopsy at the end. The lesson is not "it was sarcoid". The lesson is that the biopsy should have been month one.
Sources
Retrieved from PubMed, read on Oct 22, 2026.
- Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and detection of sarcoidosis: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 2020. doi:10.1164/rccm.202002-0251ST
- von Bartheld MB, Dekkers OM, Szlubowski A, et al. Endosonography vs conventional bronchoscopy for the diagnosis of sarcoidosis: the GRANULOMA randomized clinical trial. JAMA 2013. doi:10.1001/jama.2013.5823
- Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007. doi:10.1086/521259
- Azar MM, Hage CA. Laboratory diagnostics for histoplasmosis. J Clin Microbiol 2017. doi:10.1128/JCM.02430-16
- Rybicki BA, Iannuzzi MC, Frederick MM, et al. Familial aggregation of sarcoidosis: a case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med 2001. doi:10.1164/ajrccm.164.11.2106001